Long-term treatment with raloxifene, but not bisphosphonates, reduces circulating sclerostin levels in postmenopausal women
Summary We determined whether suppression of sclerostin levels by estrogen treatment was mediated by anti-resorptive effect. Raloxifene, but not bisphosphonates, suppressed circulating sclerostin concentration, suggesting that sclerostin may mediate the action of estrogen on bone metabolism, indepen...
Gespeichert in:
| Veröffentlicht in: | Osteoporosis international 2012-04, Vol.23 (4), p.1235-1243 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1243 |
|---|---|
| container_issue | 4 |
| container_start_page | 1235 |
| container_title | Osteoporosis international |
| container_volume | 23 |
| creator | Chung, Y. E. Lee, S. H. Lee, S.-Y. Kim, S.-Y. Kim, H.-H. Mirza, F. S. Lee, S.-K. Lorenzo, J. A. Kim, G. S. Koh, J.-M. |
| description | Summary
We determined whether suppression of sclerostin levels by estrogen treatment was mediated by anti-resorptive effect. Raloxifene, but not bisphosphonates, suppressed circulating sclerostin concentration, suggesting that sclerostin may mediate the action of estrogen on bone metabolism, independently of their anti-resorptive effects.
Introduction
Circulating sclerostin concentrations are higher in postmenopausal than in premenopausal women, and estrogen treatment suppresses sclerostin levels in both men and women. We determined whether anti-resorptives may suppress the circulating sclerostin levels.
Methods
We conducted a retrospective observational study. Eighty postmenopausal women were treated with raloxifene for 19.4 ± 7.7 months (
n
= 16), bisphosphonates for 19.2 ± 6.7 months (
n
= 32), or were untreated (
n
= 32) for 17.1 ± 4.6 months. Plasma sclerostin concentrations were measured before and after treatment.
Results
Plasma sclerostin levels after treatment were significantly lower in the raloxifene than in the control group (55.8 ± 23.4 pmol/l vs. 92.1 ± 50.4 pmol/l,
p
= 0.046), but were similar between the bisphosphonate and control groups. Relative to baseline, raloxifene treatment markedly reduced plasma sclerostin concentration (−40.7 ± 22.8%,
p
|
| doi_str_mv | 10.1007/s00198-011-1675-1 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_968183290</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2609877671</sourcerecordid><originalsourceid>FETCH-LOGICAL-c402t-ef81ccbac0e2753ffcdad596f56ba6c6bb75f3ca8a4a56687d39f2f3ad4da3063</originalsourceid><addsrcrecordid>eNp1kUuPFCEUhYnROG3rD3BjiBs3g_IoqGJpJr6STtxo4o5Q1KWnJhSUQDka_7x0etTExAXhcvnO4ZKD0FNGXzJK-1eFUqYHQhkjTPWSsHtoxzohCNdK3kc7qkVPdMe-XKBHpdzQptG6f4guOFOKSjns0M9DikdSIS-4ZrB1gVjx7VyvcbYhfZ89RLjE41ZxTBWPc1mv02lFW6Fc4gzT5qBgN2e3BVvneMTFBciptBoH-Aah4FatrdG802q3YgO-Te3wGD3wNhR4crfv0ee3bz5dvSeHj-8-XL0-ENdRXgn4gTk3WkeB91J47yY7Sa28VKNVTo1jL71wdrCdlUoN_SS0517YqZusoErs0Yuz75rT1w1KNctcHIRgI6StGK0GNgiuaSOf_0PepC3HNpzRfKCs5w3cI3aGXPtlyeDNmufF5h-GUXPKxZxzMS0Xc8rFsKZ5dme8jQtMfxS_g2gAPwOlXcUj5L8v_9_1F5-QnHI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>928017218</pqid></control><display><type>article</type><title>Long-term treatment with raloxifene, but not bisphosphonates, reduces circulating sclerostin levels in postmenopausal women</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Chung, Y. E. ; Lee, S. H. ; Lee, S.-Y. ; Kim, S.-Y. ; Kim, H.-H. ; Mirza, F. S. ; Lee, S.-K. ; Lorenzo, J. A. ; Kim, G. S. ; Koh, J.-M.</creator><creatorcontrib>Chung, Y. E. ; Lee, S. H. ; Lee, S.-Y. ; Kim, S.-Y. ; Kim, H.-H. ; Mirza, F. S. ; Lee, S.-K. ; Lorenzo, J. A. ; Kim, G. S. ; Koh, J.-M.</creatorcontrib><description>Summary
We determined whether suppression of sclerostin levels by estrogen treatment was mediated by anti-resorptive effect. Raloxifene, but not bisphosphonates, suppressed circulating sclerostin concentration, suggesting that sclerostin may mediate the action of estrogen on bone metabolism, independently of their anti-resorptive effects.
Introduction
Circulating sclerostin concentrations are higher in postmenopausal than in premenopausal women, and estrogen treatment suppresses sclerostin levels in both men and women. We determined whether anti-resorptives may suppress the circulating sclerostin levels.
Methods
We conducted a retrospective observational study. Eighty postmenopausal women were treated with raloxifene for 19.4 ± 7.7 months (
n
= 16), bisphosphonates for 19.2 ± 6.7 months (
n
= 32), or were untreated (
n
= 32) for 17.1 ± 4.6 months. Plasma sclerostin concentrations were measured before and after treatment.
Results
Plasma sclerostin levels after treatment were significantly lower in the raloxifene than in the control group (55.8 ± 23.4 pmol/l vs. 92.1 ± 50.4 pmol/l,
p
= 0.046), but were similar between the bisphosphonate and control groups. Relative to baseline, raloxifene treatment markedly reduced plasma sclerostin concentration (−40.7 ± 22.8%,
p
< 0.001), with respect to both control (−7.5 ± 29.1%) and bisphosphonate (−3.1 ± 35.2%) groups. Changes in bone-specific alkaline phosphatase and osteocalcin levels showed reverse associations with sclerostin concentration changes in the raloxifene (
γ
= −0.505,
p
= 0.017) and control (
γ
= −0.410,
p
= 0.020) groups.
Conclusions
Raloxifene, but not bisphosphonates, significantly suppressed circulating sclerostin concentration, suggesting that sclerostin may mediate the action of estrogen on bone metabolism, independently of their anti-resorptive effects.</description><identifier>ISSN: 0937-941X</identifier><identifier>EISSN: 1433-2965</identifier><identifier>DOI: 10.1007/s00198-011-1675-1</identifier><identifier>PMID: 21660558</identifier><language>eng</language><publisher>London: Springer-Verlag</publisher><subject>Aged ; Alkaline phosphatase ; Alkaline Phosphatase - blood ; Biomarkers - blood ; Bisphosphonates ; Bone Density - drug effects ; Bone Density Conservation Agents - administration & dosage ; Bone Density Conservation Agents - pharmacology ; Bone Density Conservation Agents - therapeutic use ; Bone Morphogenetic Proteins - blood ; Bone Morphogenetic Proteins - drug effects ; Bone turnover ; Bones ; Diphosphonates - administration & dosage ; Diphosphonates - pharmacology ; Diphosphonates - therapeutic use ; Drug Administration Schedule ; Drug therapy ; Endocrinology ; Estrogen receptors ; Estrogens ; Female ; Genetic Markers - drug effects ; Humans ; Medicine ; Medicine & Public Health ; Menopause ; Metabolism ; Middle Aged ; Original Article ; Orthopedics ; Osteocalcin ; Osteocalcin - blood ; Osteoporosis ; Osteoporosis, Postmenopausal - blood ; Osteoporosis, Postmenopausal - drug therapy ; Osteoporosis, Postmenopausal - physiopathology ; Post-menopause ; Raloxifene ; Raloxifene Hydrochloride - administration & dosage ; Raloxifene Hydrochloride - pharmacology ; Raloxifene Hydrochloride - therapeutic use ; Retrospective Studies ; Rheumatology ; Selective Estrogen Receptor Modulators - administration & dosage ; Selective Estrogen Receptor Modulators - pharmacology ; Selective Estrogen Receptor Modulators - therapeutic use ; SOST protein</subject><ispartof>Osteoporosis international, 2012-04, Vol.23 (4), p.1235-1243</ispartof><rights>International Osteoporosis Foundation and National Osteoporosis Foundation 2011</rights><rights>International Osteoporosis Foundation and National Osteoporosis Foundation 2012</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c402t-ef81ccbac0e2753ffcdad596f56ba6c6bb75f3ca8a4a56687d39f2f3ad4da3063</citedby><cites>FETCH-LOGICAL-c402t-ef81ccbac0e2753ffcdad596f56ba6c6bb75f3ca8a4a56687d39f2f3ad4da3063</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00198-011-1675-1$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00198-011-1675-1$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21660558$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chung, Y. E.</creatorcontrib><creatorcontrib>Lee, S. H.</creatorcontrib><creatorcontrib>Lee, S.-Y.</creatorcontrib><creatorcontrib>Kim, S.-Y.</creatorcontrib><creatorcontrib>Kim, H.-H.</creatorcontrib><creatorcontrib>Mirza, F. S.</creatorcontrib><creatorcontrib>Lee, S.-K.</creatorcontrib><creatorcontrib>Lorenzo, J. A.</creatorcontrib><creatorcontrib>Kim, G. S.</creatorcontrib><creatorcontrib>Koh, J.-M.</creatorcontrib><title>Long-term treatment with raloxifene, but not bisphosphonates, reduces circulating sclerostin levels in postmenopausal women</title><title>Osteoporosis international</title><addtitle>Osteoporos Int</addtitle><addtitle>Osteoporos Int</addtitle><description>Summary
We determined whether suppression of sclerostin levels by estrogen treatment was mediated by anti-resorptive effect. Raloxifene, but not bisphosphonates, suppressed circulating sclerostin concentration, suggesting that sclerostin may mediate the action of estrogen on bone metabolism, independently of their anti-resorptive effects.
Introduction
Circulating sclerostin concentrations are higher in postmenopausal than in premenopausal women, and estrogen treatment suppresses sclerostin levels in both men and women. We determined whether anti-resorptives may suppress the circulating sclerostin levels.
Methods
We conducted a retrospective observational study. Eighty postmenopausal women were treated with raloxifene for 19.4 ± 7.7 months (
n
= 16), bisphosphonates for 19.2 ± 6.7 months (
n
= 32), or were untreated (
n
= 32) for 17.1 ± 4.6 months. Plasma sclerostin concentrations were measured before and after treatment.
Results
Plasma sclerostin levels after treatment were significantly lower in the raloxifene than in the control group (55.8 ± 23.4 pmol/l vs. 92.1 ± 50.4 pmol/l,
p
= 0.046), but were similar between the bisphosphonate and control groups. Relative to baseline, raloxifene treatment markedly reduced plasma sclerostin concentration (−40.7 ± 22.8%,
p
< 0.001), with respect to both control (−7.5 ± 29.1%) and bisphosphonate (−3.1 ± 35.2%) groups. Changes in bone-specific alkaline phosphatase and osteocalcin levels showed reverse associations with sclerostin concentration changes in the raloxifene (
γ
= −0.505,
p
= 0.017) and control (
γ
= −0.410,
p
= 0.020) groups.
Conclusions
Raloxifene, but not bisphosphonates, significantly suppressed circulating sclerostin concentration, suggesting that sclerostin may mediate the action of estrogen on bone metabolism, independently of their anti-resorptive effects.</description><subject>Aged</subject><subject>Alkaline phosphatase</subject><subject>Alkaline Phosphatase - blood</subject><subject>Biomarkers - blood</subject><subject>Bisphosphonates</subject><subject>Bone Density - drug effects</subject><subject>Bone Density Conservation Agents - administration & dosage</subject><subject>Bone Density Conservation Agents - pharmacology</subject><subject>Bone Density Conservation Agents - therapeutic use</subject><subject>Bone Morphogenetic Proteins - blood</subject><subject>Bone Morphogenetic Proteins - drug effects</subject><subject>Bone turnover</subject><subject>Bones</subject><subject>Diphosphonates - administration & dosage</subject><subject>Diphosphonates - pharmacology</subject><subject>Diphosphonates - therapeutic use</subject><subject>Drug Administration Schedule</subject><subject>Drug therapy</subject><subject>Endocrinology</subject><subject>Estrogen receptors</subject><subject>Estrogens</subject><subject>Female</subject><subject>Genetic Markers - drug effects</subject><subject>Humans</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Menopause</subject><subject>Metabolism</subject><subject>Middle Aged</subject><subject>Original Article</subject><subject>Orthopedics</subject><subject>Osteocalcin</subject><subject>Osteocalcin - blood</subject><subject>Osteoporosis</subject><subject>Osteoporosis, Postmenopausal - blood</subject><subject>Osteoporosis, Postmenopausal - drug therapy</subject><subject>Osteoporosis, Postmenopausal - physiopathology</subject><subject>Post-menopause</subject><subject>Raloxifene</subject><subject>Raloxifene Hydrochloride - administration & dosage</subject><subject>Raloxifene Hydrochloride - pharmacology</subject><subject>Raloxifene Hydrochloride - therapeutic use</subject><subject>Retrospective Studies</subject><subject>Rheumatology</subject><subject>Selective Estrogen Receptor Modulators - administration & dosage</subject><subject>Selective Estrogen Receptor Modulators - pharmacology</subject><subject>Selective Estrogen Receptor Modulators - therapeutic use</subject><subject>SOST protein</subject><issn>0937-941X</issn><issn>1433-2965</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp1kUuPFCEUhYnROG3rD3BjiBs3g_IoqGJpJr6STtxo4o5Q1KWnJhSUQDka_7x0etTExAXhcvnO4ZKD0FNGXzJK-1eFUqYHQhkjTPWSsHtoxzohCNdK3kc7qkVPdMe-XKBHpdzQptG6f4guOFOKSjns0M9DikdSIS-4ZrB1gVjx7VyvcbYhfZ89RLjE41ZxTBWPc1mv02lFW6Fc4gzT5qBgN2e3BVvneMTFBciptBoH-Aah4FatrdG802q3YgO-Te3wGD3wNhR4crfv0ee3bz5dvSeHj-8-XL0-ENdRXgn4gTk3WkeB91J47yY7Sa28VKNVTo1jL71wdrCdlUoN_SS0517YqZusoErs0Yuz75rT1w1KNctcHIRgI6StGK0GNgiuaSOf_0PepC3HNpzRfKCs5w3cI3aGXPtlyeDNmufF5h-GUXPKxZxzMS0Xc8rFsKZ5dme8jQtMfxS_g2gAPwOlXcUj5L8v_9_1F5-QnHI</recordid><startdate>20120401</startdate><enddate>20120401</enddate><creator>Chung, Y. E.</creator><creator>Lee, S. H.</creator><creator>Lee, S.-Y.</creator><creator>Kim, S.-Y.</creator><creator>Kim, H.-H.</creator><creator>Mirza, F. S.</creator><creator>Lee, S.-K.</creator><creator>Lorenzo, J. A.</creator><creator>Kim, G. S.</creator><creator>Koh, J.-M.</creator><general>Springer-Verlag</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7RV</scope><scope>7TS</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20120401</creationdate><title>Long-term treatment with raloxifene, but not bisphosphonates, reduces circulating sclerostin levels in postmenopausal women</title><author>Chung, Y. E. ; Lee, S. H. ; Lee, S.-Y. ; Kim, S.-Y. ; Kim, H.-H. ; Mirza, F. S. ; Lee, S.-K. ; Lorenzo, J. A. ; Kim, G. S. ; Koh, J.-M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c402t-ef81ccbac0e2753ffcdad596f56ba6c6bb75f3ca8a4a56687d39f2f3ad4da3063</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Aged</topic><topic>Alkaline phosphatase</topic><topic>Alkaline Phosphatase - blood</topic><topic>Biomarkers - blood</topic><topic>Bisphosphonates</topic><topic>Bone Density - drug effects</topic><topic>Bone Density Conservation Agents - administration & dosage</topic><topic>Bone Density Conservation Agents - pharmacology</topic><topic>Bone Density Conservation Agents - therapeutic use</topic><topic>Bone Morphogenetic Proteins - blood</topic><topic>Bone Morphogenetic Proteins - drug effects</topic><topic>Bone turnover</topic><topic>Bones</topic><topic>Diphosphonates - administration & dosage</topic><topic>Diphosphonates - pharmacology</topic><topic>Diphosphonates - therapeutic use</topic><topic>Drug Administration Schedule</topic><topic>Drug therapy</topic><topic>Endocrinology</topic><topic>Estrogen receptors</topic><topic>Estrogens</topic><topic>Female</topic><topic>Genetic Markers - drug effects</topic><topic>Humans</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Menopause</topic><topic>Metabolism</topic><topic>Middle Aged</topic><topic>Original Article</topic><topic>Orthopedics</topic><topic>Osteocalcin</topic><topic>Osteocalcin - blood</topic><topic>Osteoporosis</topic><topic>Osteoporosis, Postmenopausal - blood</topic><topic>Osteoporosis, Postmenopausal - drug therapy</topic><topic>Osteoporosis, Postmenopausal - physiopathology</topic><topic>Post-menopause</topic><topic>Raloxifene</topic><topic>Raloxifene Hydrochloride - administration & dosage</topic><topic>Raloxifene Hydrochloride - pharmacology</topic><topic>Raloxifene Hydrochloride - therapeutic use</topic><topic>Retrospective Studies</topic><topic>Rheumatology</topic><topic>Selective Estrogen Receptor Modulators - administration & dosage</topic><topic>Selective Estrogen Receptor Modulators - pharmacology</topic><topic>Selective Estrogen Receptor Modulators - therapeutic use</topic><topic>SOST protein</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chung, Y. E.</creatorcontrib><creatorcontrib>Lee, S. H.</creatorcontrib><creatorcontrib>Lee, S.-Y.</creatorcontrib><creatorcontrib>Kim, S.-Y.</creatorcontrib><creatorcontrib>Kim, H.-H.</creatorcontrib><creatorcontrib>Mirza, F. S.</creatorcontrib><creatorcontrib>Lee, S.-K.</creatorcontrib><creatorcontrib>Lorenzo, J. A.</creatorcontrib><creatorcontrib>Kim, G. S.</creatorcontrib><creatorcontrib>Koh, J.-M.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Physical Education Index</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Osteoporosis international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chung, Y. E.</au><au>Lee, S. H.</au><au>Lee, S.-Y.</au><au>Kim, S.-Y.</au><au>Kim, H.-H.</au><au>Mirza, F. S.</au><au>Lee, S.-K.</au><au>Lorenzo, J. A.</au><au>Kim, G. S.</au><au>Koh, J.-M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Long-term treatment with raloxifene, but not bisphosphonates, reduces circulating sclerostin levels in postmenopausal women</atitle><jtitle>Osteoporosis international</jtitle><stitle>Osteoporos Int</stitle><addtitle>Osteoporos Int</addtitle><date>2012-04-01</date><risdate>2012</risdate><volume>23</volume><issue>4</issue><spage>1235</spage><epage>1243</epage><pages>1235-1243</pages><issn>0937-941X</issn><eissn>1433-2965</eissn><abstract>Summary
We determined whether suppression of sclerostin levels by estrogen treatment was mediated by anti-resorptive effect. Raloxifene, but not bisphosphonates, suppressed circulating sclerostin concentration, suggesting that sclerostin may mediate the action of estrogen on bone metabolism, independently of their anti-resorptive effects.
Introduction
Circulating sclerostin concentrations are higher in postmenopausal than in premenopausal women, and estrogen treatment suppresses sclerostin levels in both men and women. We determined whether anti-resorptives may suppress the circulating sclerostin levels.
Methods
We conducted a retrospective observational study. Eighty postmenopausal women were treated with raloxifene for 19.4 ± 7.7 months (
n
= 16), bisphosphonates for 19.2 ± 6.7 months (
n
= 32), or were untreated (
n
= 32) for 17.1 ± 4.6 months. Plasma sclerostin concentrations were measured before and after treatment.
Results
Plasma sclerostin levels after treatment were significantly lower in the raloxifene than in the control group (55.8 ± 23.4 pmol/l vs. 92.1 ± 50.4 pmol/l,
p
= 0.046), but were similar between the bisphosphonate and control groups. Relative to baseline, raloxifene treatment markedly reduced plasma sclerostin concentration (−40.7 ± 22.8%,
p
< 0.001), with respect to both control (−7.5 ± 29.1%) and bisphosphonate (−3.1 ± 35.2%) groups. Changes in bone-specific alkaline phosphatase and osteocalcin levels showed reverse associations with sclerostin concentration changes in the raloxifene (
γ
= −0.505,
p
= 0.017) and control (
γ
= −0.410,
p
= 0.020) groups.
Conclusions
Raloxifene, but not bisphosphonates, significantly suppressed circulating sclerostin concentration, suggesting that sclerostin may mediate the action of estrogen on bone metabolism, independently of their anti-resorptive effects.</abstract><cop>London</cop><pub>Springer-Verlag</pub><pmid>21660558</pmid><doi>10.1007/s00198-011-1675-1</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0937-941X |
| ispartof | Osteoporosis international, 2012-04, Vol.23 (4), p.1235-1243 |
| issn | 0937-941X 1433-2965 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_968183290 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Aged Alkaline phosphatase Alkaline Phosphatase - blood Biomarkers - blood Bisphosphonates Bone Density - drug effects Bone Density Conservation Agents - administration & dosage Bone Density Conservation Agents - pharmacology Bone Density Conservation Agents - therapeutic use Bone Morphogenetic Proteins - blood Bone Morphogenetic Proteins - drug effects Bone turnover Bones Diphosphonates - administration & dosage Diphosphonates - pharmacology Diphosphonates - therapeutic use Drug Administration Schedule Drug therapy Endocrinology Estrogen receptors Estrogens Female Genetic Markers - drug effects Humans Medicine Medicine & Public Health Menopause Metabolism Middle Aged Original Article Orthopedics Osteocalcin Osteocalcin - blood Osteoporosis Osteoporosis, Postmenopausal - blood Osteoporosis, Postmenopausal - drug therapy Osteoporosis, Postmenopausal - physiopathology Post-menopause Raloxifene Raloxifene Hydrochloride - administration & dosage Raloxifene Hydrochloride - pharmacology Raloxifene Hydrochloride - therapeutic use Retrospective Studies Rheumatology Selective Estrogen Receptor Modulators - administration & dosage Selective Estrogen Receptor Modulators - pharmacology Selective Estrogen Receptor Modulators - therapeutic use SOST protein |
| title | Long-term treatment with raloxifene, but not bisphosphonates, reduces circulating sclerostin levels in postmenopausal women |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T17%3A57%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Long-term%20treatment%20with%20raloxifene,%20but%20not%20bisphosphonates,%20reduces%20circulating%20sclerostin%20levels%20in%20postmenopausal%20women&rft.jtitle=Osteoporosis%20international&rft.au=Chung,%20Y.%20E.&rft.date=2012-04-01&rft.volume=23&rft.issue=4&rft.spage=1235&rft.epage=1243&rft.pages=1235-1243&rft.issn=0937-941X&rft.eissn=1433-2965&rft_id=info:doi/10.1007/s00198-011-1675-1&rft_dat=%3Cproquest_cross%3E2609877671%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=928017218&rft_id=info:pmid/21660558&rfr_iscdi=true |